Host cell pathways affecting HPV oncoprotein stability

The term "Host cell pathways affecting HPV oncoprotein stability" refers to a heterogeneous set of cellular mechanisms and pathways within human host cells that determine the abundance and stability of human papillomavirus (HPV) oncoproteins—primarily E6 and E7. These pathways include those involved in protein degradation (e.g., proteasome pathway), ubiquitin ligases (such as RNF168), DNA damage response (DDR), cell cycle regulation (e.g., retinoblastoma protein/pRB), key signaling pathways like Hippo, and others that are hijacked or disrupted by HPV infection[1][2][5][6]. These pathways are not a single molecular entity but a collective term for diverse biological processes manipulated by HPV to promote oncogenesis, including the inactivation of p53 and pRB by E6 and E7, dysregulation of DNA repair and cell cycle checkpoints, and disruption of apoptosis[1][2][3][4]. Because this term does not refer to a specific molecule, protein, or therapeutic target, but rather to a broad functional concept, it cannot be mapped appropriately to a canonical single-target format. Key context: - pRB (retinoblastoma protein) and associated cell cycle regulators stabilize the HPV E7 oncoprotein, enhancing its half-life in infected cells[5]. - HPV oncoproteins E6 and E7 destabilize tumor suppressor proteins (such as p53 and pRB) and manipulate DDR, cell cycle, and apoptotic pathways via interaction with host cell machinery[1][2][3][4][6]. - The pathways manipulated by HPV contribute to cancer progression by fostering genome instability, defective cell cycle checkpoints, and resistance to apoptosis[1][2][3].